US4642316A
(en)
*
|
1985-05-20 |
1987-02-10 |
Warner-Lambert Company |
Parenteral phenytoin preparations
|
US6071923A
(en)
*
|
1994-09-16 |
2000-06-06 |
Bar-Ilan University |
Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
|
US5730977A
(en)
|
1995-08-21 |
1998-03-24 |
Mitsui Toatsu Chemicals, Inc. |
Anti-VEGF human monoclonal antibody
|
EP0827742A1
(fr)
|
1996-09-04 |
1998-03-11 |
Vrije Universiteit Brussel |
Utilisation des inhibiteurs de l'histone déacétylase pour le traitement de la fibrose ou de la cirrhose
|
HUP0103985A2
(hu)
*
|
1998-10-13 |
2002-02-28 |
Fujisawa Pharmaceutical Co., Ltd. |
Ciklikus tetrapeptid, és annak felhasználása
|
US20070148228A1
(en)
*
|
1999-02-22 |
2007-06-28 |
Merrion Research I Limited |
Solid oral dosage form containing an enhancer
|
MXPA01010891A
(es)
*
|
1999-04-28 |
2002-11-07 |
Univ Texas |
Composiciones y metodos para el tratamiento contra el cancer mediante la inhibicion selectiva del factor de crecimiento endotelial vascular (vegf).
|
DK1233958T3
(da)
*
|
1999-11-23 |
2011-10-17 |
Methylgene Inc |
Hæmmere af histondeacetylase
|
GB0023983D0
(en)
*
|
2000-09-29 |
2000-11-15 |
Prolifix Ltd |
Therapeutic compounds
|
ATE430567T1
(de)
|
2000-09-29 |
2009-05-15 |
Topotarget Uk Ltd |
Carbaminsäurederivate enthaltend eine amidgruppe zur behandlung von malaria
|
WO2002030879A2
(fr)
*
|
2000-09-29 |
2002-04-18 |
Prolifix Limited |
Composes d'acide carbamique comprenant une liaison sulfonamide en tant qu'inhibiteurs de hdac
|
JPWO2002074298A1
(ja)
*
|
2001-03-21 |
2004-07-08 |
小野薬品工業株式会社 |
Il−6産生阻害剤
|
DE60227658D1
(de)
|
2001-05-02 |
2008-08-28 |
Univ California |
Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
|
WO2003016254A1
(fr)
*
|
2001-08-09 |
2003-02-27 |
Ono Pharmaceutical Co., Ltd. |
Composes derives d'acide carboxylique et medicaments comprenant ces composes comme principe actif
|
RU2298414C2
(ru)
|
2001-08-21 |
2007-05-10 |
Астеллас Фарма Инк. |
Медицинское применение ингибитора гистоновой дезацетилазы и способ оценки его противоопухолевого действия
|
US6897220B2
(en)
*
|
2001-09-14 |
2005-05-24 |
Methylgene, Inc. |
Inhibitors of histone deacetylase
|
EP1293205A1
(fr)
|
2001-09-18 |
2003-03-19 |
G2M Cancer Drugs AG |
Acide valproique et ses dérivés pour la polythérapie du cancer humain et pour le traitement de la métastase de tumeurs et de la maladie residuelle imperceptible
|
ATE382343T1
(de)
*
|
2002-01-11 |
2008-01-15 |
Matthias Rath |
Polyphenole enthaltende pharmazeutische nahrungsmittelergänzungsformel und ihre anwendung in der krebsbehandlung
|
AU2003215112A1
(en)
|
2002-02-07 |
2003-09-02 |
Axys Pharmaceuticals |
Novel bicyclic hydroxamates as inhibitors of histone deacetylase
|
CA2476434A1
(fr)
*
|
2002-02-15 |
2003-08-28 |
Sloan-Kettering Institute For Cancer Research |
Methode de traitement des maladies mediees par la thioredoxine (trx)
|
US20050288227A1
(en)
*
|
2002-02-15 |
2005-12-29 |
Marks Paul A |
Use of thioredoxin measurements for diagnostics and treatments
|
US20070060614A1
(en)
*
|
2002-03-04 |
2007-03-15 |
Bacopoulos Nicholas G |
Methods of treating cancer with hdac inhibitors
|
US7148257B2
(en)
*
|
2002-03-04 |
2006-12-12 |
Merck Hdac Research, Llc |
Methods of treating mesothelioma with suberoylanilide hydroxamic acid
|
PL372239A1
(en)
*
|
2002-03-04 |
2005-07-11 |
Aton Pharma, Inc. |
Methods of inducing terminal differentiation
|
US20040132825A1
(en)
*
|
2002-03-04 |
2004-07-08 |
Bacopoulos Nicholas G. |
Methods of treating cancer with HDAC inhibitors
|
EP1485353B1
(fr)
|
2002-03-13 |
2011-08-24 |
Janssen Pharmaceutica NV |
Nouveaux inhibiteurs de l'histone deacetylase
|
US7629343B2
(en)
|
2002-04-03 |
2009-12-08 |
Topotarget Uk Limited |
Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors
|
TWI319387B
(en)
|
2002-04-05 |
2010-01-11 |
Astrazeneca Ab |
Benzamide derivatives
|
WO2003087066A1
(fr)
*
|
2002-04-11 |
2003-10-23 |
Sk Chemicals, Co., Ltd. |
Derives d'acide hydroxamique $g(a),$g(b)-insatures et leur utilisation comme inhibiteurs de l'histone desacetylase
|
WO2003088954A1
(fr)
*
|
2002-04-15 |
2003-10-30 |
Sloan-Kettering Institute For Cancer Research |
Polytherapie pour le traitement de cancer
|
US8883148B2
(en)
*
|
2002-04-26 |
2014-11-11 |
Asan Laboratories Company (Cayman), Limited |
Prevention of joint destruction
|
GB0209715D0
(en)
|
2002-04-27 |
2002-06-05 |
Astrazeneca Ab |
Chemical compounds
|
DE10233412A1
(de)
|
2002-07-23 |
2004-02-12 |
4Sc Ag |
Neue Verbindungen als Histondeacetylase-Inhibitoren
|
WO2004013130A1
(fr)
|
2002-08-02 |
2004-02-12 |
Argenta Discovery Limited |
Acides substitues thienylhydroxamiques utilises en tant qu'inhibiteurs d'histone desacetylase
|
GB0226370D0
(en)
|
2002-11-12 |
2002-12-18 |
Novartis Ag |
Organic compounds
|
US20080004311A1
(en)
*
|
2002-11-12 |
2008-01-03 |
Alcon, Inc. |
Histone deacetylase inhibitors for treating degenerative diseases of the eye
|
ITMI20030025A1
(it)
|
2003-01-10 |
2004-07-11 |
Italfarmaco Spa |
Derivati dell'acido idrossammico ad attivita' antinfiammatoria.
|
US7135493B2
(en)
|
2003-01-13 |
2006-11-14 |
Astellas Pharma Inc. |
HDAC inhibitor
|
US20050222013A1
(en)
*
|
2003-01-16 |
2005-10-06 |
Georgetown University |
Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy
|
TW200424174A
(en)
|
2003-02-06 |
2004-11-16 |
Hoffmann La Roche |
New TP diamide
|
AU2003900608A0
(en)
|
2003-02-11 |
2003-02-27 |
Fujisawa Pharmaceutical Co., Ltd. |
Hdac inhibitor
|
US7244751B2
(en)
|
2003-02-14 |
2007-07-17 |
Shenzhen Chipscreen Biosciences Ltd. |
Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
|
EP1597390A4
(fr)
|
2003-02-18 |
2006-12-27 |
Maxcyte Inc |
Introduction d'antigenes dans des cellules par electroporation
|
CA2518318A1
(fr)
|
2003-03-17 |
2004-09-30 |
Takeda San Diego, Inc. |
Inhibiteurs d'histone deacetylase
|
TW200424187A
(en)
|
2003-04-04 |
2004-11-16 |
Hoffmann La Roche |
New oxime derivatives and their use as pharmaceutically active agents
|
AU2004230889B2
(en)
|
2003-04-07 |
2008-03-13 |
Pharmacyclics Llc |
Hydroxamates as therapeutic agents
|
US20040220242A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Leland Shapiro |
Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
|
JP5416338B2
(ja)
|
2003-05-09 |
2014-02-12 |
デューク ユニバーシティ |
Cd20特異的抗体およびその使用方法
|
CN1791396A
(zh)
|
2003-05-21 |
2006-06-21 |
诺瓦提斯公司 |
组蛋白脱乙酰基酶抑制剂与化疗剂的组合
|
EP1491188A1
(fr)
*
|
2003-06-25 |
2004-12-29 |
G2M Cancer Drugs AG |
Utilisation topique de l'acide valproique pour traiter des maladies de la peau
|
ATE462426T1
(de)
*
|
2003-08-26 |
2010-04-15 |
Merck Hdac Res Llc |
Verwendung von saha zur behandlung von mesotheliom
|
CA2535889A1
(fr)
|
2003-08-29 |
2005-03-17 |
Aton Pharma, Inc. |
Methodes combinees de traitement du cancer
|
JP2007511212A
(ja)
*
|
2003-11-14 |
2007-05-10 |
ホルム,ペル・ゾンネ |
新規アデノウイルス、それをコードする核酸及びその使用
|
WO2005051430A1
(fr)
*
|
2003-11-14 |
2005-06-09 |
Per Sonne Holm |
Nouvelle utilisation d'adenovirus et d'acides nucleiques les codant
|
AU2003290412A1
(en)
|
2003-12-30 |
2005-07-21 |
Council Of Scientific And Industrial Research |
Arginine hydrochloride enhances chaperone-like activity of alpha crystallin
|
GB0401876D0
(en)
*
|
2004-01-28 |
2004-03-03 |
Vereniging Het Nl Kanker I |
New use for cancer antigen
|
WO2005085864A1
(fr)
*
|
2004-02-27 |
2005-09-15 |
The Government Of The United States Of America, Asrepresented By The Secretary Of The Department Of Health And Human Services |
Essais pharmacodynamiques à cytométrie de flux
|
PT1591109E
(pt)
*
|
2004-04-30 |
2008-09-05 |
Desitin Arzneimittel Gmbh |
Formulação exibindo libertação bifásica compreendendo um inibidor da desacetilase de histona
|
PL1781321T3
(pl)
|
2004-08-02 |
2014-07-31 |
Zenyth Operations Pty Ltd |
Sposób leczenia raka zawierający antagonistę VEGF-B
|
JPWO2006014024A1
(ja)
*
|
2004-08-06 |
2008-05-01 |
小野薬品工業株式会社 |
精神神経系疾患治療剤
|
CN101001851B
(zh)
*
|
2004-08-09 |
2011-04-20 |
安斯泰来制药有限公司 |
具有作为组蛋白脱乙酰酶(hdac)抑制剂的活性的羟基酰胺化合物
|
WO2006060382A2
(fr)
*
|
2004-11-30 |
2006-06-08 |
Trustees Of The University Of Pennsylvania |
Utilisation d'inhibiteurs de hdac et/ou dnmt dans le traitement d'une lesion ischemique
|
FR2879204B1
(fr)
|
2004-12-15 |
2007-02-16 |
Lab Francais Du Fractionnement |
Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
|
EP1830864A2
(fr)
*
|
2004-12-31 |
2007-09-12 |
Per Sonne Holm |
Adenovirus a region e1 absente et leur utilisation
|
MX2007008781A
(es)
*
|
2005-01-21 |
2007-09-11 |
Astex Therapeutics Ltd |
Compuestos farmaceuticos.
|
NZ599464A
(en)
*
|
2005-02-03 |
2014-03-28 |
Topotarget Uk Ltd |
Combination therapies using hdac inhibitors
|
US20060229237A1
(en)
*
|
2005-04-07 |
2006-10-12 |
Yih-Lin Chung |
Treatment of gastrointestinal distress
|
GB0509225D0
(en)
*
|
2005-05-05 |
2005-06-15 |
Chroma Therapeutics Ltd |
Inhibitors of enzymatic activity
|
CN102579417B
(zh)
|
2005-05-13 |
2014-11-26 |
托波塔吉特英国有限公司 |
Hdac抑制剂的药物制剂
|
EP1743654A1
(fr)
*
|
2005-07-15 |
2007-01-17 |
TopoTarget Germany AG |
Utilisation d'inhibiteurs d'histone déacetylase avec des composés AINS pour traiter le cancer et/ou les maladies inflammatoires
|
CA2619568A1
(fr)
*
|
2005-08-19 |
2007-03-01 |
Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services |
Formulations topiques d'inhibiteurs d'histone desacetylase et procedes d'utilisation de celles-ci
|
RU2008108221A
(ru)
*
|
2005-09-07 |
2009-10-20 |
Плекссикон, Инк. (Us) |
Соединения, активные в отношении ppar (рецепторов активаторов пролиферации пероксисом)
|
WO2007049262A1
(fr)
|
2005-10-27 |
2007-05-03 |
Berand Limited |
Procedes et compositions pour favoriser la croissance neuronale et le traitement de l'asociabilite et des troubles affectifs
|
AU2006313517B2
(en)
*
|
2005-11-10 |
2013-06-27 |
Topotarget Uk Limited |
Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent
|
US8445198B2
(en)
*
|
2005-12-01 |
2013-05-21 |
Medical Prognosis Institute |
Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
|
KR101415354B1
(ko)
*
|
2006-02-22 |
2014-07-04 |
4에스체 악티엔게젤샤프트 |
Eg5 키네신 조절제로서의 인돌로피리딘
|
MX2008010799A
(es)
*
|
2006-02-22 |
2008-11-06 |
4Sc Ag |
Indolopiridinas como moduladores de quinesina eg5.
|
GB0606096D0
(en)
|
2006-03-27 |
2006-05-03 |
Cbmm Sa |
Screening method
|
EP1839656A1
(fr)
*
|
2006-03-31 |
2007-10-03 |
TopoTarget Germany AG |
Utilisation d'acide valproic pour le traitement topique de doux de modérer vulgaris d'acné
|
EP2026805A1
(fr)
*
|
2006-05-08 |
2009-02-25 |
Astex Therapeutics Limited |
Combinaisons pharmaceutiques de dérivés de diazole pour le traitement du cancer
|
JP2009539862A
(ja)
*
|
2006-06-09 |
2009-11-19 |
メリオン リサーチ Iii リミテッド |
強化剤を含む固体経口投与剤形
|
WO2008011603A2
(fr)
*
|
2006-07-20 |
2008-01-24 |
Wisconsin Alumni Research Foundation |
Modulation de la voie du signal notch1 pour le traitement de tumeurs neuroendocrines
|
JP2010509370A
(ja)
*
|
2006-11-10 |
2010-03-25 |
シンダックス ファーマシューティカルズ,インク. |
癌の治療用のERα+リガンドとヒストンデアセチラーゼ阻害剤との組み合わせ
|
US8796330B2
(en)
*
|
2006-12-19 |
2014-08-05 |
Methylgene Inc. |
Inhibitors of histone deacetylase and prodrugs thereof
|
WO2008090534A1
(fr)
|
2007-01-26 |
2008-07-31 |
Berand Limited |
Procédés et compositions destinés à l'inhibition d'un gain de poids excessif, la réduction de comportements alimentaires inappropriés et l'inhibition de l'hyperphagie pour le traitement de l'obésité
|
US7915245B2
(en)
*
|
2007-02-01 |
2011-03-29 |
The Board Of Regents Of The University Of Texas System |
Methods and compositions of trail-death receptor agonists/activators
|
WO2008101121A2
(fr)
*
|
2007-02-14 |
2008-08-21 |
Dana-Farber Cancer Institute, Inc. |
Procédés et compositions concernant la régulation de promoteurs par les protéines muc1 et klf
|
WO2008136838A1
(fr)
*
|
2007-05-04 |
2008-11-13 |
Trustees Of Dartmouth College |
Nouveaux dérivés d'amide de cddo et leurs procédés d'utilisation
|
WO2008154402A2
(fr)
*
|
2007-06-06 |
2008-12-18 |
University Of Maryland, Baltimore |
Inhibiteurs de hdac et médicaments ciblant une hormone pour le traitement du cancer
|
US20090246198A1
(en)
*
|
2008-03-31 |
2009-10-01 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors and methods of use thereof
|
US20090270497A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Pharmacyclics, Inc. |
Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
|
WO2009137649A2
(fr)
*
|
2008-05-07 |
2009-11-12 |
The Trustees Of The University Of Pennsylvania |
Procédés de traitement du cancer de la thyroïde
|